Nuformix
GBX0.16
4
-GBX0.02-11.43% Friday 15:25
Estadísticas
Día Alto
0.19
Día de baja
0.16
52W Alto
0.44
52W Bajo
0.15
Volumen
5,008,363
Volumen medio
4,293,815
Cap. de mercado
1.31M
Relación P/U
-
Rentabilidad por dividendo
-
Dividendo
-
Próximamente
Ganancias
27NovEsperado
GPA esperado
No aplica
GPA actual
No aplica
La gente también sigue a
Esta lista se basa en las watchlists de personas que siguen a NFX.LSE en Stock Events. Esto no es una recomendación de inversión.
Competidores
Esta lista es un análisis basado en eventos recientes del mercado. No es una recomendación de inversión.
Astrazeneca
AZN.LSE
Cap. de mercado205.78B
GSK
GSK.LSE
Cap. de mercado67.59B
Synairgen
SNG.LSE
Cap. de mercado8.1M
HUTCHMED (China) Limited
HCM.LSE
Cap. de mercado2.27B
Indivior
INDV.LSE
Cap. de mercado1.23B
Acerca de
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Show more...
Director general
Dr. Daniel John Gooding
Empleados
3
País
GB
ISIN
GB00BYW79Y38